Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - oxervate
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf9944720e0617f59c4092a55c234abd3
identifier: http://ema.europa.eu/identifier
/EU/1/17/1197/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: OXERVATE 20 micrograms/ml eye drops, solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f9944720e0617f59c4092a55c234abd3
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/17/1197/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - oxervate
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
OXERVATE contains the active substance cenegermin. Cenegermin is a type of nerve growth factor (a human protein) which is naturally present on the eye surface.
OXERVATE is used to treat adults with moderate or severe neurotrophic keratitis . This is a disease affecting the cornea (the transparent layer in the front part of the eye) which causes defects on the outer surface of the cornea that do not heal naturally or corneal ulcers. OXERVATE is intended to allow the healing of the cornea.
Do not use OXERVATE:
Warnings and precautions Only use this medicine in your affected eye(s). Talk to your doctor before using this medicine:
Treatment with OXERVATE may cause you mild to moderate eye discomfort such as eye pain. If you experience a severe eye reaction seek medical advice from your doctor.
Contact lenses could interfere with the correct use of this medicine. If you wear contact lenses remove them before using this medicine and wait 15 minutes after using this medicine before reinserting them.
Children and adolescents This medicine should not be used in children and adolescents below 18 years of age, as there is not enough information about its use in this age group.
Other medicines and OXERVATE Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
You should wait at least 15 minutes before or after using OXERVATE if you use any other eye drops. This will help to avoid one eye drop diluting the other eye drop. If you also use an eye ointment or gel or an eye drop with a thick consistency, you should use OXERVATE first, and then wait at least 15 minutes before using the other medicine.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
The use of this medicine should be avoided during pregnancy. Talk to your doctor if you are pregnant or think you may be pregnant.
It is not known if this medicine passes into breast milk. Talk to your doctor before breast-feeding your baby, as a decision must be made whether to stop breast-feeding or to avoid or stop OXERVATE therapy.
Driving and using machines Your vision may be temporarily blurred immediately after using this medicine. If this happens, wait until your vision clears before you drive or use machines.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is 1 drop in the affected eye 6 times a day at 2-hourly intervals, starting in the morning (i.e. 6 drops per day within 12 hours). You should continue your treatment for 8 weeks.
Instructions for use Follow these instructions carefully and ask your doctor or pharmacist if there is anything you do not understand. Ocular use.
You will receive an insulated container containing a weekly carton of OXERVATE and a separate delivery system (composed of medical devices intended for withdrawing and administering the medicine).
The weekly carton contains 7 vials of OXERVATE (1 vial per day of the week). Remove the weekly carton of OXERVATE from the insulated container and store it in a fridge as soon as you can (and in any case no later than 5 hours from when you receive the medicine from your pharmacist). Since at the pharmacy this medicine is stored in a freezer, in case treatment is started right away after receiving the weekly carton, you will have to wait until the first vial is thawed (this could take up to 30 minutes).
Take an individual vial of this medicine from the fridge in the morning (always at the same time each morning), and prepare it in the following way:
1
2
3
The multi-dose vial of OXERVATE is now ready for use (1 drop in the affected eye every 2 hours six times a day). The vial can be stored in the fridge or below 25 C throughout the day, but should not be frozen.
To withdraw and administer each dose of this medicine, follow the steps below:
4
5
6
7
Repeat the above process (from picture 4 onwards) every 2 hours 6 times a day. Use a new disinfectant wipe and a new pipette each time.
If you use drops in both eyes, repeat the above instructions for your other eye using a new pipette (in this case, you will need to use 2 vials per day).
Discard the used vial at the end of each day (even if there is still some liquid left in it), and in any case no later than 12 hours from the time you connected the vial adapter to it.
You will receive a new supply of OXERVATE each week, for the duration of the treatment period. To ensure accurate dosing every 2 hours, you could set an alarm as a reminder for dosing.
To control that six doses have been taken at the end of each treatment day, you should use the weekly dose recording card provided with the delivery system. On that card you should write down the date of the first use of the weekly supply, the time of the vial opening (i.e. when you connect the vial adapter to the vial) and track each time you use an eye drop of this medicine, over the week.
If you use more OXERVATE than you should If you use more than you should, flush the affected eye with lukewarm water. Do not put in any more drops until it is time for your next regular dose. Using more OXERVATE than is recommended is not likely to be harmful. Continue with your next dose as scheduled.
If you forget to use OXERVATE Continue with your next dose as scheduled. Do not use a double dose to make up for the forgotten dose. You can give the missed dose 2 hours after your last scheduled dose of the day, provided this is still within 12 hours from first opening the daily vial. Do not use more than 6 drops each day in the affected eye(s). If you stop using OXERVATE
The lesion or ulcer in your eye will worsen and could lead to infections or impaired vision. Speak to your doctor first if you intend to stop using OXERVATE.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The majority of side effects occur generally in and around the eyes.
The following side effects have been reported:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and vial label after EXP . The expiry date refers to the last day of that month.
Store the weekly carton containing 7 vials of OXERVATE in the fridge (2-8 C).
After the vial adapter is connected to the vial, it can be stored in the fridge or below 25 C. Discard the used vial at the end of the day (even if there is still some liquid left in it), and in any case no later than 12 hours from the time you connected the vial adapter to it. The pipettes included in the delivery system are single-use only. Each pipette should be discarded immediately after using, even if there is still some liquid left in it.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What OXERVATE contains
What OXERVATE looks like and contents of the pack OXERVATE is a clear, colourless eye drops, solution.
It is supplied in multi-dose glass vials. Each vial contains 1 ml eye drops, solution. The vials are contained in a weekly cardboard carton containing 7 vials. 7 vial adapters, 42 pipettes, 42 disinfectant wipes and a dose recording card are provided separately from the vials. Extra adapter (1), pipettes (3) and wipes (3) are included as spares.
Pack size: 7 multi-dose vials.
Marketing Authorisation Holder Domp farmaceutici S.p.A. Via Santa Lucia, 6 20122 Milano Italy
Manufacturer Domp farmaceutici S.p.A. Via Campo di Pile 67100 L Aquila Italy
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-f9944720e0617f59c4092a55c234abd3
Resource Composition:
Generated Narrative: Composition composition-en-f9944720e0617f59c4092a55c234abd3
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/17/1197/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - oxervate
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf9944720e0617f59c4092a55c234abd3
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf9944720e0617f59c4092a55c234abd3
identifier:
http://ema.europa.eu/identifier
/EU/1/17/1197/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: OXERVATE 20 micrograms/ml eye drops, solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en